 Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F the Company, an international biopharmaceutical company, today reported its financial results for the full year ended December 31, 2019 and provided an update on recent operational and clinical developments. Cash and cash equivalents were EUR 11.1 million as of December 31, 2019 compared to EUR 19.5 million as of December 31, 2018. 